CholremCholesterol & arterial science

News

The cyclodextrin field in motion

Developments at Cholrem and across the field that Cholrem helped open.

Cholrem · November 2026

Three-vessel coronary case report submitted for peer review

Cholrem has submitted a case report to a cardiology journal documenting severe three-vessel coronary disease, bypass declined, reduced to patent arteries on CT after eleven months of nightly HPβCD therapy with no other treatment. Publication details will be posted here.

See the images →
Field · November 2026

FDA approves Lembaz™, the first cyclodextrin medicine

Beren Therapeutics’ HPβCD product was approved by the US FDA for Niemann-Pick disease type C, the first FDA licence for the molecule, granted for intrathecal use. Beren raised US$300 million earlier in 2026.

Field · November 2026

FDA clears cyclodextrin trial in coronary artery disease

Cyclarity Therapeutics received FDA clearance to begin a Phase 1b study of an engineered cyclodextrin in patients with coronary artery disease, with CT coronary angiography before and after dosing. Its Phase 1 ran at Monash University’s Victorian Heart Institute in Australia. The FDA has now cleared a coronary study of the class, using the same imaging Cholrem has worked with for years.

Field · October 2026

Intravenous HPβCD drug application filed

Rafael Holdings submitted a New Drug Application for intravenous HPβCD in Niemann-Pick disease type C, adding to the systemic human safety record for the molecule.

Cholrem · 2026

Coronary calcification regression published

Cholrem’s multi-centre longitudinal analysis reports serial, scanner-matched coronary calcium scores falling on the high-viscosity formulation, a result no drug class has produced in a controlled trial.

Read the paper →
Cholrem · 2026

Synthesis paper in preparation

A synthesis of Cholrem’s seven papers lays each finding against the predictions already in the independent literature. Nine of twelve were predicted before Cholrem observed them in humans.